High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.
Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free.
Lyttelton
M P
MP
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospitals NHS Trust, London, UK.
Newlands
E S
ES
Giles
C
C
Bower
M
M
Guimaraes
A
A
O'Reilly
S
S
Rustin
G J
GJ
Samson
D
D
Kanfer
E J
EJ
D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D018237:Germinoma / Q000188:drug therapy*; D005919:Glomerular Filtration Rate; D006801:Humans; D008297:Male; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome
D016190:Carboplatin